Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

CD39 Antikörper (Extracellular)

ENTPD1 Reaktivität: Human WB, IF (cc), LCI Wirt: Kaninchen Polyclonal unconjugated
Produktnummer ABIN7043112
  • Target Alle CD39 (ENTPD1) Antikörper anzeigen
    CD39 (ENTPD1) (Ectonucleoside Triphosphate diphosphohydrolase 1 (ENTPD1))
    Bindungsspezifität
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 398-411, Extracellular
    Reaktivität
    • 79
    • 36
    • 26
    • 4
    • 4
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    Human
    Wirt
    • 42
    • 38
    • 9
    • 1
    • 1
    • 1
    Kaninchen
    Klonalität
    • 56
    • 35
    • 1
    Polyklonal
    Konjugat
    • 48
    • 7
    • 6
    • 6
    • 4
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser CD39 Antikörper ist unkonjugiert
    Applikation
    • 38
    • 36
    • 23
    • 18
    • 12
    • 12
    • 4
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Live Cell Imaging (LCI)
    Verwendungszweck
    A Rabbit Polyclonal Antibody to CD39
    Spezifität
    Extracellular loop
    Kreuzreaktivität
    Human, Maus
    Homologie
    14 amino acid residues identical, rat - 11,Mouse - 12
    Produktmerkmale
    Anti-CD39 (extracellular) Antibody (ABIN7043112, ABIN7044809 and ABIN7044810)) is a highly specific antibody directed against an epitope of the human protein. The antibody can be used in western blot and indirect live cell flow cytometry applications. It has been designed to recognize ENTPD1 from rat, mouse, and human samples.
    Aufreinigung
    Affinity purified on immobilized antigen.
    Immunogen

    Immunogen: Synthetic peptide

    Immunogen Sequence: (C)KTSYAGVKEKYLSE, corresponding to amino acid residues 398-411 of human CD39

    Isotyp
    IgG
    Top Product
    Discover our top product ENTPD1 Primärantikörper
  • Applikationshinweise

    Antigen preadsorption control: 1 μg peptide per 1 μg antibody

    Application Dilutions Immunohistochemistry paraffin embedded sections ihc: N/A

    Application Dilutions Western blot wb: 1:200-1:400

    Kommentare

    Negative Control: BLP-NT065

    Blocking Peptide: BLP-NT065

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Lyophilized
    Rekonstitution
    Recosntitute with double distilled water (DDW) to a concentration of 1.0 mg/mL.
    Konzentration
    1 mg/mL
    Buffer
    PBS pH 7.4
    Lagerung
    4 °C,-20 °C
    Informationen zur Lagerung

    Storage before reconstitution: The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C.

    Storage after reconstitution: The reconstituted solution can be stored at 4°C for up to 1 week. For longer periods, small aliquots should be stored at -20°C. Avoid multiple freezing and thawing. Centrifuge all antibody preparations before use (10000 x g 5 min).

  • Target
    CD39 (ENTPD1) (Ectonucleoside Triphosphate diphosphohydrolase 1 (ENTPD1))
    Andere Bezeichnung
    ENTPD1 (ENTPD1 Produkte)
    Hintergrund
    Ectonucleoside triphosphate diphosphohydrolase 1, NTPDase 1, Ecto-ATP diphosphohydrolase 1, Ecto-ATPDase 1, Ecto-apyrase, Lymphoid cell activation antigen, ENTPD1,Ectonucleoside triphosphate diphosphohydrolase 1 (NTPDase1, ENTPD1, or CD39) is an enzyme that catalyzes the phosphohydrolysis of extracellular adenosine triphosphate (eATP) and diphosphate (eADP), that are released following inflammatory stress and cell injury, to adenosine monophosphate (AMP). AMP is then used by the ecto-5'-nucleotidase CD73 to synthesize adenosine1.Hydrolysis of adenosine triphosphate and adenosine diphosphate, performed by CD39, suppresses the immune system and inhibits T-cell and Natural killer (NK) cell responses. This inhibition has a role in promoting Chronic lymphocytic leukemia (CLL) and hence it is proposed that blockade or inhibition of CD39 may be a target for new immune therapy for CLL2. CD39 activity is also related to the occurrence of calcific aortic valve disease (CAVD)3, and to various other types of immune responses4. In addition, CD39 plays a dominant role in the purinergic regulation of inflammation1.The transcription of CD39 is constitutive in microvascular endothelium and certain immune cells. The modulated expression of NTPDase1 has been closely associated with inflammatory cytokines, oxidative stress and hypoxia in vitro and in vivo5.Localization of CD39 within lipid rafts suggests that this ecto-enzyme may be involved in cell-cell contact and signaling6.CD39 is a part of the ectonucleoside triphosphate dyphosphohydrolases (eNTDPase) protein family which shares a unique structural feature: instead of being anchored in the membrane by a single transmembrane domain or lipid link like other ectoenzymes, these proteins contain two transmembrane domains, one at each end of the protein. The active site lies in the large extracellular region. In addition, all family members share a set of short sequences termed apyrase conserved regions (ACRs)7.

    Alternative names: Ectonucleoside triphosphate diphosphohydrolase 1, NTPDase 1, Ecto-ATP diphosphohydrolase 1, Ecto-ATPDase 1, Ecto-apyrase, Lymphoid cell activation antigen, ENTPD1, CD39
    Gen-ID
    953
    NCBI Accession
    NM_001776
    UniProt
    P49961
Sie sind hier:
Kundenservice